ESOMEPRAZOLE - leitarniðurstöður

abbvie deutschland gmbh & co. kg - atogepant - mígreni kvilla - aquipta is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

odomzo

sun pharmaceutical industries europe b.v. - sonidegib tvífosfat - krabbamein, basalfrumur - Æxlishemjandi lyf - odomzo er ætlað til meðferðar hjá fullorðnum sjúklingum með staðbundið langt gengið grunnfrumukrabbamein (bcc) sem ekki er hægt að lækna með skurðaðgerð eða geislameðferð.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

mycapssa

amryt pharmaceuticals dac - octreotide acetate - acromegaly - hinsveiflur og heilahimnubólur og hliðstæður - mycapssa is indicated for maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogues.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

cabometyx

ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - Æxlishemjandi lyf - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy. cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.